Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 10.5% during trading on Wednesday . The company traded as high as $5.48 and last traded at $5.37, with a volume of 3,450,867 shares. The stock had previously closed at $4.86.

Several analysts recently issued reports on the company. Vetr downgraded ZIOPHARM Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 price target for the company. in a report on Monday, April 18th. Wells Fargo & Co. reiterated a “sell” rating on shares of ZIOPHARM Oncology in a report on Wednesday, June 8th. Griffin Securities reiterated a “buy” rating and issued a $21.00 price target on shares of ZIOPHARM Oncology in a report on Tuesday, June 7th. Raymond James Financial Inc. assumed coverage on ZIOPHARM Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating for the company. Finally, Mizuho increased their price target on ZIOPHARM Oncology from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Wednesday, May 11th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. ZIOPHARM Oncology currently has a consensus rating of “Buy” and an average target price of $9.55.

The firm’s 50 day moving average is $5.28 and its 200 day moving average is $6.73. The firm’s market capitalization is $703.15 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.52 million. During the same period in the prior year, the business earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 525.0% on a year-over-year basis. Analysts predict that ZIOPHARM Oncology Inc. will post ($0.88) EPS for the current fiscal year.

Several large investors recently modified their holdings of the stock. California State Teachers Retirement System raised its stake in shares of ZIOPHARM Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares during the period. Swiss National Bank raised its stake in shares of ZIOPHARM Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the period. Morgan Stanley raised its stake in shares of ZIOPHARM Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the period. Finally, California Public Employees Retirement System raised its stake in shares of ZIOPHARM Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.